SCHEDULE 13G/A: T. Rowe Price Associates Discloses Passive 0.2% Stake in IGM Biosciences Inc.
Ownership Disclosure
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.2% in IGM Biosciences Inc.'s common stock as of January 31, 2025.
Summary
- T. Rowe Price Associates, Inc., an investment adviser based in Maryland, has filed an Amendment No. 7 to Schedule 13G.
- The filing discloses their beneficial ownership in IGM Biosciences Inc. (CUSIP: 449585108) common stock.
- As of January 31, 2025, T. Rowe Price Associates, Inc. beneficially owns 65,940 shares of IGM Biosciences Inc.
- This ownership represents 0.2% of the total class of securities.
- T. Rowe Price Associates, Inc. holds sole voting power and sole dispositive power over all 65,940 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of passive ownership and does not contain information that would significantly alter the sentiment towards the company. The stake is very small (0.2%).
Positives
- The disclosure indicates continued passive investment by a reputable institutional investor, T. Rowe Price Associates, Inc., in IGM Biosciences Inc.
Negatives
- The reported ownership stake of 0.2% is very small, indicating a minor position for T. Rowe Price Associates, Inc. in IGM Biosciences Inc.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of passive ownership by an institutional investment adviser, T. Rowe Price Associates, Inc., in a publicly traded biotechnology company, IGM Biosciences Inc. Such filings are common and reflect portfolio management decisions rather than specific industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership structure and the passive stake held by a major institutional investor. Given the small percentage, the direct impact on other shareholders is minimal.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of event which required the filing of this statement. |
| 02/07/2025 | Date of filing of the Schedule 13G Amendment No. 7. |
Keywords
IGM Biosciences Inc., T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.